Abstract CT181: A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct181
Abstract: Background: SHR-A1921 is a novel ADC composed of a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) IgG1 monoclonal antibody attached to a DNA topoisomerase I inhibitor via a tetrapeptide-based cleavable linker. Herein, we present the preliminary… read more here.
Keywords: study shr; shr a1921; patients advanced; phase ... See more keywords
A bridging immunogenicity assay for monoclonal antibody: case study with SHR-1222.
Sign Up to like & getrecommendations! Published in 2018 at "Bioanalysis"
DOI: 10.4155/bio-2017-0289
Abstract: AIM SHR-1222 is a humanized monoclonal antibody targeted to soluble sclerostin. To support the preclinical study of SHR-1222 in cynomolgus monkeys, a method for the detection of anti-drug antibodies is required. RESULTS A bridging immunogenicity… read more here.
Keywords: shr 1222; study shr; shr; monoclonal antibody ... See more keywords